Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Duct Cell Adenocarcinoma of the Pancreas: early-phase trial registry
A small indexed set (4 trials) with no open enrollment listed right now.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · none currently recruiting · #4,115 of 28,707 conditions by registered trial count
Duct Cell Adenocarcinoma of the Pancreas: 4 US clinical trials tracked, none currently recruiting.
Duct Cell Adenocarcinoma of the Pancreas is the subject of 4 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 2 of these trials.
Enrollment posture brief
Registry condition duct-cell-adenocarcinoma-of-the-pancreas
OPEN 0 | RECR 0% | LATE 0 | EARLY 4 | RANK #4115 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Duct Cell Adenocarcinoma of the Pancreas has no open enrollment in this registry pull (4 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Duct Cell Adenocarcinoma of the Pancreas on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Duct Cell Adenocarcinoma of the Pancreas is recruiting below its size-band peers.
0 of 4 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
4 total, page 1 of 1
Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas
National Cancer Institute (NCI)
NCT00085371
Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer
Yale University
NCT02047474
Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer
Edward Kim
NCT01924260
Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer
National Cancer Institute (NCI)
NCT00031694
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Duct Cell Adenocarcinoma of the Pancreas records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Duct Cell Adenocarcinoma of the Pancreas trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Duct Cell Adenocarcinoma of the Pancreas page
4 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Duct Cell Adenocarcinoma of the Pancreas trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- National Cancer Institute (NCI) sponsors the most Duct Cell Adenocarcinoma of the Pancreas trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Duct Cell Adenocarcinoma of the Pancreas condition card totals 4 registered trials; most-linked intervention triapine; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.